Recombinant IgG1 control antibodies and concentrated supernatants from engineered B cell culture were tested against the CLDN6-expressing tumor cell line PA-1, which express CLDN6 at high levels (Supplementary Figures 1E, F). Here, CLDN6 is linked to neoplasm.